T2952
Tetrabenazine
≥98% (HPLC), VMAT inhibitor, solid
别名:
9,10-Dimethoxy-1,3,4,6,7,11b-hexahydro-3-isobutyl-(rel 3R,11bR)-2H-benzo[a]quinolizin-2-one
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C19H27NO3
化学文摘社编号:
分子量:
317.42
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
200-383-6
MDL number:
Beilstein/REAXYS Number:
40090
产品名称
Tetrabenazine, ≥98% (HPLC), solid
Quality Level
assay
≥98% (HPLC)
form
solid
solubility
DMSO: >10 mg/mL, H2O: insoluble
originator
Roche
storage temp.
2-8°C
SMILES string
COc1cc2CCN3C[C@@H](CC(C)C)C(=O)CC3c2cc1OC
InChI
1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1
InChI key
MKJIEFSOBYUXJB-GDBMZVCRSA-N
Application
Tetrabenazine has been used for dopamine uptake assays in mouse brain cells1. Tetrabenazine has also been used for non-specific binding assays in postnuclear supernatants derived from PC-12 and CV-1 cells2.
Biochem/physiol Actions
Tetrabenazine is a reversible type 2 vesicular monoamine transporter (VMAT) inhibitor.
Tetrabenazine is a reversible type 2 vesicular monoamine transporter (VMAT) inhibitor. It depletes dopamine stores.
Features and Benefits
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Preparation Note
Tetrabenazine is soluble in DMSO at a concentration that is greater than 10 mg/ml and is insoluble in water.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Mahabuba Jahan et al.
EJNMMI research, 1(1), 33-33 (2012-01-05)
Fluorine-18 dihydrotetrabenazine [DTBZ] analogues, which selectively target the vesicular monoamine transporter 2 [VMAT2], have been extensively studied for in vivo quantification of beta cell mass by positron-emission tomography [PET]. This study describes a novel deuterated radioligand [18F]fluoroethyl [FE]-DTBZ-d4, aimed to
Sinéad M Murphy et al.
Annals of neurology, 72(4), 481-490 (2012-10-31)
Since the introduction of the Orphan Drug Act in 1983, designed to promote development of treatments for rare diseases, at least 378 orphan drugs have been approved. Incentives include financial support, tax credits, and perhaps most importantly, extended market exclusivity.
Using the affective bias test to predict drug-induced negative affect: implications for drug safety.
S A Stuart et al.
British journal of pharmacology, 174(19), 3200-3210 (2017-08-07)
Predicting the risk of drug-induced adverse psychiatric effects is important but currently not possible in non-human species. We investigated whether the affective bias test (ABT) could provide a preclinical method with translational and predictive validity. The ABT is a bowl-digging
Nicolaas I Bohnen et al.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 32(8), 1609-1617 (2012-05-10)
Parkinson's disease (PD) is a multisystem neurodegenerative disorder. Heterogeneous clinical features may reflect heterogeneous changes in different brain regions. In contrast to the pronounced nigrostriatal denervation characteristic of PD, cholinergic changes are less marked. We investigated cholinergic innervation activity in
Marc D Normandin et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 53(6), 908-916 (2012-05-11)
The ability to noninvasively measure endogenous pancreatic β-cell mass (BCM) would accelerate research on the pathophysiology of diabetes and revolutionize the preclinical development of new treatments, the clinical assessment of therapeutic efficacy, and the early diagnosis and subsequent monitoring of
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| T2952-50MG | 04061832983905 |
| T2952-10MG | 04061832983899 |
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持